Metraipolis › archive › dc_0f4dd3f2e437
BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series — Europe PMC PMID:41727688
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41727688
- DOI
- 10.3389/fendo.2026.1694805
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T02:20:14.206Z
- SHA-256 of the archived text
186aaa2b5051d57912ad1727ac9fc7abcc6d37f4367ad02af1241ce22e6a9b23- Stable URL of this page
https://metraipolis.com/documento/dc_0f4dd3f2e437
How to cite
BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series — Europe PMC PMID:41727688 — Europe PMC (en), https://europepmc.org/article/MED/41727688 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0f4dd3f2e437 (Metraipolis archive dc_0f4dd3f2e437, sha256 186aaa2b5051d57912ad1727ac9fc7abcc6d37f4367ad02af1241ce22e6a9b23)
BibTeX
@misc{dc0f4dd3f2e437,
title = {BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series — Europe PMC PMID:41727688},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41727688},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0f4dd3f2e437; sha256 186aaa2b5051d57912ad1727ac9fc7abcc6d37f4367ad02af1241ce22e6a9b23},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41727688. Agents can read the archived copy with the MCP tool read_document.